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OPEN
REVIEW
The dopamine hypothesis of bipolar affective disorder: the
state of the art and implications for treatment
AH Ashok1,2,3,4, TR Marques1,2,3,4, S Jauhar1,2,3,4, MM Nour1,2,3, GM Goodwin5, AH Young4,6 and OD Howes1,2,3,4
Bipolar affective disorder is a common neuropsychiatric disorder. Although its neurobiological underpinnings are incompletely
understood, the dopamine hypothesis has been a key theory of the pathophysiology of both manic and depressive phases of
the illness for over four decades. The increased use of antidopaminergics in the treatment of this disorder and new in vivo
neuroimaging and post-mortem studies makes it timely to review this theory. To do this, we conducted a systematic search
for post-mortem, pharmacological, functional magnetic resonance and molecular imaging studies of dopamine function
in bipolar disorder. Converging ﬁndings from pharmacological and imaging studies support the hypothesis that a state of
hyperdopaminergia, speciﬁcally elevations in D2/3 receptor availability and a hyperactive reward processing network, underlies
mania. In bipolar depression imaging studies show increased dopamine transporter levels, but changes in other aspects of
dopaminergic function are inconsistent. Puzzlingly, pharmacological evidence shows that both dopamine agonists and
antidopaminergics can improve bipolar depressive symptoms and perhaps actions at other receptors may reconcile these ﬁndings.
Tentatively, this evidence suggests a model where an elevation in striatal D2/3 receptor availability would lead to increased
dopaminergic neurotransmission and mania, whilst increased striatal dopamine transporter (DAT) levels would lead to reduced
dopaminergic function and depression. Thus, it can be speculated that a failure of dopamine receptor and transporter
homoeostasis might underlie the pathophysiology of this disorder. The limitations of this model include its reliance on
pharmacological evidence, as these studies could potentially affect other monoamines, and the scarcity of imaging evidence on
dopaminergic function. This model, if conﬁrmed, has implications for developing new treatment strategies such as reducing the
dopamine synthesis and/or release in mania and DAT blockade in bipolar depression.
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INTRODUCTION
Bipolar disorder (BD) is a severe mental illness characterised by
recurrent episodes of mania, depression or mixed states.1,2 The
lifetime prevalence of the full spectrum of bipolar disorder is
estimated to be 2–4% in the general population and it is the sixth
leading cause of disability worldwide.3–6 The costs due to BD are
immense, with annual direct healthcare costs in the USA of about
$30 billion and indirect costs of 4$120 billion.7,8
Lithium has been the mainstay of maintenance treatment for
BD for decades, together with valproate, an option that has
emerged more recently. However their modes of action have not
been well established. By contrast antidopaminergic drugs do
have well-understood class action at D2/3 receptors and have
long been used to treat acute manic episodes. However, as will be
explained below, newer drugs (particularly olanzapine and
quetiapine) have been shown to have antimanic and antidepres-
sant actions in bipolar disorder together with long-term beneﬁt in
preventing relapse to either pole of the illness.9–15 Although the
newer drugs were introduced for the treatment of schizophrenia,
they have arguably represented a bigger advance for the
management of bipolar disorder.
Despite these advances in treatment, many patients continue to
experience high levels of disability.11 Furthermore drugs may be
associated with signiﬁcant side-effect burden and the risk of
toxicity and/or teratogenicity in some instances.16–18 Hence better
understanding of pathophysiology and drug action appears
necessary to improve the use of current treatments and develop
better alternatives.
The dopamine hypothesis of BD dates back at least to the
1970s.19–21 Early incarnations focused on mania, and the parallels
between the behavioural consequences of amphetamine ingestion
and the antimanic actions of antidopaminergic drugs. If hyperdo-
paminergia underlies the development of manic symptoms, then
hypodopaminergia might underlie the depressive phase of the
illness. Thus, opposite changes in dopaminergic function were
hypothesised to underlie the opposing affective poles of the
disorder.19–21 This theory did not explain how hyper- or
hypodopaminergia would arise and subsequent versions pro-
posed an additional component to the hypothesis, where an
intrinsic dysregulation in the homoeostatic regulation of dopami-
nergic function leads to cyclical changes in dopaminergic
neurotransmission,22,23 which would further distinguish the
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Table 1. Post-mortem studies assessing the role of dopamine in bipolar disorder
Measure of Author Bipolar patients/
controls (n)
Bipolar
patients/
controls age
mean (s.d.) in
years
Method Area Cause of
death
patients/
controls
Patients’ medication Post-mortem
interval (h):
patients/
controls
Results (BD relative to
controls)
Dopamine
transporter
Rao et al.134 10/10 55 (s.e.m.:
6.6)/49
(s.e.m.: 4.3)
Western blot analysis, RNA
isolation, RT-PCR
Prefrontal Cortex Not
mentioned
Lithium: 4
Valproate: 5
Rispiridone: 1
Carbamazepine: 1
21/20 ↓ DAT protein and
mRNA levels
Lee et al.135 15/15 42.3 (9.3)/48
(10.7)
Coimmunoprecipitation and
Western blot analyses
Striatum Suicide-9/0
Non suicidal-
6/15
Dopamine antagonist:
7
33/24 ↔ DAT protein
levels
Dopamine
D1 receptor
Pantazopoulos
et al.37
15/15 58.3/61.3 In situ hybridisation Hippocampus Suicide-3/0
Non suicidal-
12/15
Dopamine antagonist:
8
21/20 ↑D1 mRNA
expression in
hippocampal sector
CA2
Kaalund et al.34 DLPFC 61/ 244
Hippocampus
31/192
Caudate nucleus
44/78
45/40
46/40
43/41
RNA extraction and
Quantitative real-time PCR
DLPFC,
hippocampus
and caudate
Not
mentioned
Dopamine antagonist:
17
Not
mentioned
↑DRD1 in DLPFC
and hippocampus.
↔ caudate nucleus
Dopamine
D2 receptor
Zhan et al.35 32/34 45 (10)/43 (7) Quantitative real-time PCR Prefrontal cortex Sucide-15/0
Non suicidal
causes-17/34
Mean lifetime
antidopaminergic
exposure:
10 071 mg
ﬂuphenazine
equivalent
37/29 ↑ D2 mRNA level in
prefrontal cortex
Glantz et al.36 14/14 42.3 (11.7)/
48.1 (10.7)
Western blot analysis and
immunohistochemistry
Temporal Cortex Suicide-9/0
Non suicidal-
6/15
Lithium: 4
Dopamine antagonist:
8
Antidepressant: 8
33/24 ↔
Kaalund et al.34 DLPFC 61/ 244
Hippocampus
31/192
Caudate nucleus
44/78
45/40
46/40
43/41
RNA extraction and
Quantitative real-time PCR
DLPFC,
hippocampus
and caudate
Not
mentioned
Dopamine antagonist:
17
Not
mentioned
↑D2L in DLPFC and
hippocampus
↔ Caudate nucleus
Lee et al.135 15/15 42.3 (9.3)/48
(10.7)
Coimmunoprecipitation and
Western blot analyses
Striatum Suicide-9/0
Non suicidal-
6/15
Dopamine antagonist:
7
33/24 ↔ D2 protein levels
D5 receptor Knable et al.38 48 data sets In situ hybridisation Hippocampus Not
mentioned
Not mentioned Not
mentioned
↑ Dopamine D5
receptor RNA in
dentate gyrus, CA1
and subiculum
Abbreviations: DAT, dopamine transporter; DLPFC, dorsolateral prefrontal cortex; PCR, polymerase chain reaction; RT-PCR, reverse transcription polymerase chain reaction.
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dopamine hypothesis of bipolar from theories of schizophrenia.24
Thus, faulty homoeostatic mechanisms responding to hyperdopa-
minergia in the manic phase of the illness are proposed to result in
an excessive reduction in dopaminergic function, rapidly leading to
a hypodopaminergic state and depression. In turn a faulty
regulatory response to hypodopaminergia leads, to a switch back to
mania.22,23 Implicit in this model is that a normalisation of
dopaminergic function leads to remission and euthymia. Clearly,
some kind of dysregulation must be required to account for the
onset of episodes, but BD is also characterised by inter-episode
mood instability.25 Any satisfactory theory must account for the
randomness of much bipolar experience as well as the cyclicity. As
current antimanic antipsychotics are all dopamine D2 receptor
blockers, their use for mania has long supported the involvement of
dopamine in mania, but the increasing use of some antidopami-
nergic drugs to treat bipolar depression and as maintenance drugs
makes it timely to review the dopamine hypothesis of BD.
Furthermore, a number of new lines of evidence relevant to the
role of dopamine, in particular from molecular and functional
neuroimaging, have developed in recent years. Thus, we synthesize
evidence from pharmacological, in vivo neuroimaging and post-
mortem studies addressing the role of the dopamine system in BD
and then consider the treatment and drug development
implications.
ANIMAL MODELS AND THEIR IMPLICATIONS FOR
UNDERSTANDING THE ROLE OF DOPAMINE IN BIPOLAR
DISORDER
Initial animal models of mania were based on amphetamine-
induced hyperlocomotion, and it was shown that lithium reverses
this behaviour.26,27 Following this, a dopamine transporter (DAT)
knockout rodent model was developed, and dopamine transpor-
ter blockers other than amphetamine (such as GBR12909) have
been used. Both these approaches have been shown to induce
manic-like behaviour, such as hyperlocomotion and increased
exploration.28,29 Subsequently, dopamine receptor stimulation
using quinipirole (a dopamine agonist) was shown to induce
manic-like behaviour.30 Interestingly, mood stabilisers such as
valproate and carbamazepine reversed these effects.30 Recently,
Sidor and colleagues demonstrated the impact of alterations in
the regulation of circardian rhythm on dopaminergic activity and
behaviour.31 In this study, mice with a mutation in a circadian
clock gene displayed a manic-like phenotype as measured by
hyperlocomotion in the daytime. Moreover, hyperlocomotion was
linked to an elevated daytime spike in ventral tegmental area
(VTA) dopaminergic activity, as well as increased dopamine
synthesis and tyrosine hydroxylase activity.31 This was further
validated using sustained optogenetic stimulation of the VTA,
which also induced hyperlocomotion behaviour.31 Taken together
this evidence suggests that hyperdopaminergia, induced either
by increased dopamine release, dopamine transporter blockade
or dopamine receptor stimulation, results in a mania-like
phenotype in rodents. In contrast, lesions in dopaminergic areas
(such as the VTA and substantia nigra) induce depressive
behaviour, such as learned helplessness.32 Moreover, optogenetic
stimulation of VTA dopaminergic neurons reverses depressive
behaviour (as assessed using the forced swim test in chronically
stressed animals).33 These models thus provide evidence that
hypodopaminergia may induce depressive-like behaviours and
hyperdopaminergia may induce manic-like behaviour. Further
research is needed to determine the key components of the
dopaminergic circuit underlying this, particularly in relation to
depressive behaviour.
POST-MORTEM STUDIES ON DOPAMINE GENE EXPRESSION IN
BIPOLAR DISORDER
Table 1 shows the post-mortem studies addressing dopaminergic
gene expression in BD. Overall the most consistent ﬁndings come
from studies on the D2 receptor expression, with two studies
suggesting that the D2 receptor is upregulated in BD in the
dorsolateral prefrontal cortex.34,35 However, to date only four
studies,28,30,34,36 have been conducted, and only two focus on the
same region (dorsolateral prefrontal cortex). Thus, this ﬁnding still
requires replication in other brain regions to determine if there is
regional speciﬁcity. The literature on other dopaminergic recep-
tors is more limited, with only two studies on the D1 receptor34,37
and one study on the D5 receptor.38 Another issue for the post-
mortem studies is that they are affected by several confounding
factors such as medication status, post-mortem interval, substance
abuse and cause of death. Antidopaminergic treatment has been
shown to increase D2/3 receptor levels in animals,39 and there is
evidence this may also occur in schizophrenia.40 This suggests that
prior treatment could also have affected the D2/3 receptor
ﬁndings in BD. Finally, data on phase-speciﬁc changes are difﬁcult
to characterise as clinical status at the time of death remains
unknown. Despite these limitations, post-mortem data supports
the notion that an abnormality within the dopaminergic path-
ways, in particular involving D2/3 receptors, might play a role in
the pathogenesis of BD.
IN VIVO IMAGING OF DOPAMINE
Dopamine in mania
We have summarised the in vivo imaging studies of mania in
Table 2. Interestingly, patients with psychotic mania showed an
elevated density of D2/3 receptors as measured by N-[11C]-
methylspiperone, when compared with healthy controls (HC) and
non-psychotic mania patients,41,42 although, as this tracer has
signiﬁcant afﬁnity for 5HT2 receptors as well,43 this ﬁnding
requires replication with more selective tracers. Moreover, no
signiﬁcant difference in the striatal D2/3 density was noted in non-
psychotic mania patients compared to HC.44 These studies also
explored the relationship between manic symptoms (as assessed
using Young’s Mania Rating Scale Score) and dopamine synthesis
capacity and D2/3 density, ﬁnding no signiﬁcant correlations
between these variables in patients with mania.41,44,45 However, in
one of these studies D2/3 density was directly correlated with
psychosis scores on the present state examination.41 Taken
together, these data suggest that psychotic symptoms in mania
may be associated with dopaminergic abnormalities, although the
same cannot be inferred in non-psychotic mania patients.
Dopamine in euthymic BD
Two studies have assessed dopamine transporters in the euthymic
state and are conﬂicting. Chang et al reported an upregulation of
the dopamine transporter in drug naive euthymic bipolar patients,
while Anand et al. observed a downregulation in a group
consisting of both euthymic bipolar and bipolar depression
patients.46,47 Additionally, one study has assessed the vesicular
monoamine transporter protein (VMAT-2), located in presynaptic
neurons and involved in the storage of dopamine. There was an
increase in VMAT-2 in the thalamus and dorsal brainstem, but no
signiﬁcant alteration in striatum, in currently euthymic patients
with a history of psychotic mania compared with HC.48 A positron
emission tomography (PET) study using [11C]-SCH23390 found
decreased D1 density in the frontal cortex but not in the striatum
of bipolar patients compared to HC, suggesting a regional
difference in D1 receptor distribution (Table 3).49
So far, only one PET study has assessed dopamine release in BD.
This study used [123I]-IBZM to measure dopamine receptor density
and release after amphetamine challenge in patients in their
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Table 2. In vivo imaging studies assessing dopamine in mania
Dopamine
system studied
Author Patients/
controls (n)
Phase of illness-number
of participants in the
given phase
Medication Tracer* Primary outcome
In patients compared with controls
Secondary outcome
Dopamine
synthesis
Yatham
et al.45
13/14 Mania (Non-
psychotic)-13
Sodium valproate [18F]DOPA ↔ FDOPA uptake rate constants in
the striatum.
After 2–6 weeks treatment with
sodium valporate, FDOPA rate
constants - ↓
No correlations were found
between YMRS and pre/post Ki
values
D2/3 receptor
availability
Yatham
et al.44
13/14 Mania (Non-
psychotic)-13
Sodium valproate [11C]raclopride ↔ Striatal D2 density.
After 2–6 weeks of treatment with
sodium valproate no change in
striatal D2 density (10 patients had
second scan).
No correlation was found between
D2 density and score of young
mania rating scale.
Similarly changes in the D2 density
did not correlate with score in the
YMRS
Pearlson
et al.41
14/12 Mania-11
(6 psychotic mania)
Depression-3
All received two scans.
Second scan was
preceded by haloperidol
lactate
[11C]N-
methylspiperone
↑ D2 density in caudate and
putamen
D2 availability directly correlated
with psychotic symptom severity
score, but no correlation with
mania symptom rating
Wong
et al.42
14/24 Mania-11 (7
psychotic)
Depression-3
Drug naive N-[11C]
methylspiperone
([11C]NMSP)
↑ D2 dopamine receptor density in
caudate were seen in psychotic
patients compared with non-
psychotic patients and healthy
controls
Abbreviations: YMRS, Young’s Mania Rating Scale; ↔ , no signiﬁcant difference. *Further details of scan and patient characteristics are given in the Supplementary Material.
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Table 3. In vivo imaging studies assessing dopamine in the depressive and euthymic phase of bipolar disease
Dopamine
system studied
Author Patients/
controls (n)
Phase of illness-
number of
participants in the
given phase
Medication Tracer Primary outcome
In patients compared with
controls
Secondary outcome
Vesicular
monoamine
transporter
protein
(VMAT-2)
Zubieta et al.48 16/16 Euthymic-16
(history of
psychotic mania)
Valproic acid; lithium;
carbamazepine; lamotrigine
[11C]
dihydrotetrabenazine
(DTBZ)
↔ Caudate
↑ Brainstem and thalamus
VMAT concentration in
brainstem and thalamus
positively correlated with the
measure of frontal executive
function
Dopamine
release
Anand et al.50 13/13 Euthymic-13 7 Drug naive and 6 were on mood
stabiliser: lithium (4) valproate (2).
After ﬁrst scan patients were
administered amphetamine
[123I]IBZM ↔ In amphetamine-
induced decrease in striatal
[123I]IBZM binding.
In patients, amphetamine-
induced decrease in [123I] IBZM
binding did not correlate with
post amphetamine YMRS score.
In healthy controls, there was
trend level correlation.
Dopamine
transporter
Anand et al.46 11/13 Depressed-6
Euthymic-5
Drug naive [11C]CFT ↓ DAT availability in caudate
nucleus in patients
No correlations were found
between YMRS/HDRS and D2
binding
Amsterdam and
Newberg136
5/46 Depression-5 Drug naive for at least a week [99mTc]
TRODAT-1
↑ Binding potential in the
posterior putamen and in
the left caudate region
Chang et al.47 17/17 Euthymic-17 Drug naive [99mTc] TRODAT-1 ↑ Striatal DAT availability No signiﬁcant difference in DAT
availability between bipolar I
and II.
D2/3 density Anand et al.50 13/13 Euthymic-13 7 Drug naive and 6 were on mood
stabiliser: lithium (4) valproate (2).
After ﬁrst scan patients were
administered amphetamine
[123I]IBZM ↔ In striatal D2 receptor
binding at baseline.
↔ In amphetamine-
induced decrease in striatal
[123I] IBZM binding.
In patients, amphetamine-
induced decrease in [123I] IBZM
binding did not correlate with
post amphetamine YMRS score.
In healthy controls, there was
trend level correlation
D1 density Suhara et al.49 10/21 Depressed-3
Manic-1
Euthymic-6
All except one were drug naive for
at least one week before scan
[11C]-SCH23390 ↓ D1, in the frontal
cortex↔ striatum
Abbreviations: DAT, dopamine transporter; DVR, distribution volume ratio; HDRS, Hamilton Depression Rating Scale; YMRS, Young’s Mania Rating Scale.
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Table 4. Functional magnetic resonance imaging studies investigating bipolar patients vs healthy controls during monetary reward tasks
Phase of illness Author BD n (%M)/ HC n (%M)a fMRI task VS ‘reward’ activity in BD vs HC Association with symptoms/dopamine antagonist medication
Anticipation Feedbacka
Manic Abler et al.70 12 BD I (58.3)/12 HC (58.3) Monetary
incentive task
↔ VS ↓ Left VS
Bermpohl et al.71 15 BD I (53.3)/26 HC (57.7) MID ↔ VS ↔ VS No association with antidopaminergic medication. Remitted BD (n= 7,
YMRSo8) OFC activation was similar to HC.
Euthymic Yip et al.82 20 BD II /NOS (60)/20 HC
(50)
MID ↔ VS (↓ r.DS) ↔ VS No correlation between subsyndromal depressive symptoms (HDRS)
and reward-related BOLD signal.
Caseras et al.72 17 BD I (36)/15 BD II (40)/
20 HC (35)
Card guessing
task
BD I: ↔VS
BD II: ↑VS
BD I:↑ left VS
(trend)
BD II:↔VS
During reward anticipation BD I had ↓VS activation vs BD II. At reward
feedback BD I had ↑ activity in right VS vs BD II (not signiﬁcant when
excluding patients taking antidopaminergic medication or co-varying
for medication load). VS activity not correlated with YMRS or HDRS.
Mason et al.76 20 BD (18=BD I, 2=BD II)
(50)/20 HC (45)
Roulette task ↑left VS (trend) ↑VS Preferential activity for high probability rewards negatively correlated
with impulsivity (DLPFC) and risk taking (DLPDC and VS)
Trost et al.81 16 BD I (37.5)/16 HC (43.8) Desire-reason
dilemma
NA ↓VS Task-appropriate bilateral VS suppression in BD correlated with
antidopaminergic dose
Nusslock et al.77 21 BD I (42.9)/20 HC (40) Card guessing
task
↑Right VS ↔VS No association with antidopaminergic medication
Dutra et al.74 24 BD I (37.5)/25 HC (40) MID (no ‘loss’
condition)
↔VS ↑VS No association with antidopaminergic medication or symptom scores
Linke et al.75 19 BD I (42.1)/19 HC (42.1) Reversal learning NA ↔VS Negative correlation between medication load and mean activation
of the right amygdala in response to reward in BD
Bipolar depression Chase et al.73 23 BD I (17.4)/37 HC (32.4) Card guessing
task
↔VS ↔VS AP associated with↓‘prediction error’ VS signal. Illness duration
associated with ↓ACC reward anticipation activation
Satterthwaite
et al.79
23 BD (21 BD I, 2 BD II)
(37)/32 HC (51)
Monetary reward
task
NA ↔VS BDI correlated with diminished reward-related (win4loss) activation
of bilateral VS, anterior and posterior cingulate, and anterior insula
No effect of antidopaminergic dose on reward-related BOLD signal
Redlich et al.78 33 BD I (51.5)/34 HC (52.9) Card guessing
task
Not analysed ↓VS No association with medication load or symptom scores
Heterogeneous Singh et al.80 24 adolescent BD1 (54)/
24 HC (37)
MID ↔VS ↔VS YMRS score associated with ↓VS activation during reward
anticipation, when MID was preceded by ‘positive mood induction’
Abbreviations: ACC, anterior cingulate cortex; BD(I/II), bipolar disorder (I/II); BDI, beck depression inventory; DLPFC, dorsolateral prefrontal cortex; DS, dorsal striatum; fMRI, functional magnetic resonance
imaging; HC, healthy controls; HDRS, Hamilton Depression Rating Scale; MDD, major depressive disorder; MID, monetary incentive delay task; NOS, not otherwise speciﬁed; YMRS, Young Mania Rating Scale.
Results presented are restricted to ventral striatum (VS), which has been most consistently implicated in event-related fMRI reward tasks. Values given as mean (s.d.) unless stated otherwise. aSubject
characteristics and reward feedback analysis contrasts are given in Supplementary Table 2.
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euthymic phase of illness, and found no signiﬁcant differences
between patients and HC.50
Dopamine in bipolar depression
There is a paucity of literature on dopamine release and post-
synaptic dopamine receptor density. Findings on dopamine
transporter density remains controversial, with one study showing
an increase in bipolar depressive patients when compared with
HC, whilst the others, which recruited both euthymic and
depressed patients, noted a reduction (Table 3).21,26
DOPAMINE, REWARD PROCESSING AND BIPOLAR DISORDER:
FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDIES
Dopaminergic projections from the VTA to the ventral striatum
(VS) (including nucleus accumbens) and prefrontal cortex have an
important role in reward processing51,52 and have also been
implicated in the processing of other behaviourally salient
stimuli.53,54 The word 'reward' implies three related functional
elements: a positive reinforcer for learning, movement towards a
desired object and subjective/emotional choices. The brain
processes underlying reinforcement and movement can be
quantitatively assessed using speciﬁc behavioural tasks and single
cell or optogenetic recording in animals.55 Tasks that inform
emotion per se are increasingly being performed in man but
necessarily with less direct measures of neuronal activity.
Investigations in animals have shown that individual neurons
signal reward-related information in the midbrain (substantia
nigra and VTA), striatum, orbitofrontal cortex, amygdala and
associated structures. Most dopamine neurons in the substantia
nigra and VTA show brief, phasic responses that reﬂect the
difference in value between received reward and predicted
reward. The precise relationship between cell ﬁring and function
is still debated, but it would be misleading to think of dopamine
neurotransmission simply in terms of a pleasure signal.56 Changes
in BOLD signal occur in the human nucleus accumbens,
striatum and frontal cortex over a time course of seconds in
response to anticipated reward.57 Consistent with the animal
literature, event-related functional magnetic resonance imaging
(fMRI) reward paradigms have demonstrated robust activation of
the ventral striatum in relation to both the anticipation and
receipt of reward,58–61 presumably related to dopaminergic
neurotransmission.57,62–69
In BD several fMRI studies employing reward tasks support the
existence of abnormal reward-related neural activity in the VS and
frontal cortex (task paradigms and results for VS summarised in
Supplementary Table 2 and Table 4, respectively).61,70–82 This
provides another indirect line of evidence for a dopaminergic
abnormality in this disorder. We discuss the evidence in relation to
speciﬁc mood polarities below.
Bipolar mania
During cued reward anticipation Abler et al. reported that
medicated manic patients had reduced activity to high- vs no-
anticipated reward in the VTA,70 owing to increased neural activity
for no-reward-predicting cues in BD patients. Three studies using
monetary reward tasks found no difference in VS activation to
cued reward anticipation between patients and controls.70,71,80
Two of these studies did, however, ﬁnd elevated frontal cortex
activity during reward anticipation in manic patients.71,80 During
reward feedback Abler et al. reported reduced activity in response
to receipt of probabilistic rewards in the VS in BD compared with
HC.70 This ﬁnding has not been replicated in more recent studies
in patients with current manic symptoms71 or a recent manic
episode.80
Together, these studies suggest hyperactive neuronal activity in
putatively dopaminergic circuits of the reward system in currently
manic patients, particularly during cue-induced reward anticipa-
tion. The precise nature of this abnormality, however, remains
uncertain.
Euthymic bipolar
Euthymic patients are of particular interest because they are at risk
of mania. In these patients abnormalities in dopaminergic function
would then indicate how vulnerability might be mediated. In
medicated euthymic bipolar I patients, VS and prefrontal cortex
activity to cued reward anticipation has been variously reported as
increased,76,77 and no different72,74 compared with controls.
During reward feedback VS activity in euthymic bipolar I patients
has been reported as increased,72,74,76 no different75,77 and
decreased (in euthymic and mildly depressed patients),81 com-
pared with controls. Reward feedback related activation in the
frontal cortex has also variously been reported as elevated,75,76
decreased (in euthymic and mildly depressed patients)81 or no
different74,77 in bipolar I patients compared with controls. In
euthymic bipolar II patients Caseras et al. reported elevated VS
and prefrontal cortex activity for cued reward anticipation
compared with controls.72 This ﬁnding, however, was not
replicated in a more recent study of medication-naive bipolar II
patients, which instead reported reduced anticipation-related
activity in the right dorsal striatum in patients.82 Both studies
reported no difference in VS activity during reward feedback in
patients vs controls. Increased responses in the anticipatory phase
of the monetary incentive delay task have been described in
euthymic unipolar patients.83 Careful comparison of unipolar with
bipolar cases will be necessary to distinguish network dysfunction
associated with (hypo)mania from that with depression. All such
studies need to be adequately powered and preferably address
pre-speciﬁed hypotheses, not always a standard observed in
imaging studies.
In summary, the precise nature of the abnormality of reward-
related activity in euthymic bipolar patients remains unclear.
However, abnormalities of reward processing are probably not
conﬁned to the manic phase of the illness. Important differences
in task structure and the post hoc choice of analysis contrasts
between these studies may account for the inconsistencies and
non-replication. Further studies are required to explore the
suggested differences between euthymic bipolar I, bipolar II and
unipolar disorder.
Bipolar depression
Three studies have compared monetary reward processing in
medicated depressed bipolar I patients and HC. Only one study
analysed activity during cued reward anticipation; it reported no
difference in anticipation-related activity between patients and HC
in VS or prefrontal cortex, although there was blunting in the
anterior cingulate cortex in depressed patients (bipolar and
unipolar). Neural activity related to outcome anticipation per se
was increased in left ventrolateral prefrontal cortex in patients
with bipolar-1 disorder, compared with healthy controls or
patients with unipolar depressive disorder; it may represent a
more generalised ‘arousal’ response in the bipolar depressed
group.73 Ventral striatal and prefrontal activation during reward
feedback in bipolar depressive patients has been reported both as
similar to controls73,79 and decreased.78
Recent fMRI studies and meta-analyses have demonstrated
blunted activation of the reward network in the ventral striatum
and frontal cortex in schizophrenia,84–86 as well as major
depressive disorder and alcohol addiction.84 In contrast, the fMRI
ﬁndings in bipolar disorder summarised above do not provide
consistent evidence for blunting. It may be important to consider
only studies in the manic state, because depressed or even
euthymic (often dysthymic) bipolar patients may well show
blunting.82 In mania there was increased frontal activation to
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reward anticipation in two out of three studies. If this ﬁnding is
conﬁrmed in further studies, including direct comparisons with
patients with schizophrenia, it could point to a key difference in
the reward network between mania and schizophrenia. To date a
small number of studies have compared reward processing in
bipolar disorder with schizophrenia70 or major depressive
disorder.73,78 Of these, one study reported blunted VS activation
in depressed patients diagnosed with bipolar disorder compared
with major depressive disorder, at reward feedback.78 Only one
study compared reward processing in schizophrenia and manic
patients with controls.70 Patients with schizophrenia and healthy
controls showed an activation in the VTA on expectation of
monetary rewards and nucleus accumbens activation during
receipt vs omission of rewards. Manic patients, however, showed
reduced differential activation in the nucleus accumbens on
receipt vs omission of rewards compared to the healthy control
subjects. Taken together with the ﬁndings in the frontal cortex
discussed above, this small study does suggest that in mania there
is a deﬁcit in prediction error processing not seen in schizo-
phrenia. It may further imply bipolar disorder speciﬁc changes in
dopaminergic function, although how much of the fMRI response
is driven by disrupted dopaminergic function remains to be
determined. Further studies investigating differences in reward
processing between bipolar disorder and other psychotic and
affective disorders, and across illness phases, will shed light on the
reward processing abnormalities speciﬁc to bipolar disorder.
PHARMACOLOGICAL EVIDENCE
Dopaminergic manipulations and the induction of mania
The role of dopaminergic abnormalities in BD has been
extensively investigated using a variety of pharmacological
approaches (Table 5). Firstly, studies have shown that psychosti-
mulants, particularly amphetamine, cause mania-like symptoms in
healthy volunteers.87–90 Further, there are several case series of
manic and hypomanic episodes in Parkinson’s disease patients
treated with Levodopa.91–93 Bromocriptine, another dopamine
agonist, has also been shown to induce manic symptoms.94,95
Similarly, an increased risk of hypomania/mania was observed in
bipolar patients who received stimulant (methylphenidate,
amphetamine or modaﬁnil) augmentation for bipolar
depression.96 Secondly, pharmacological strategies to deplete
tyrosine, a dopamine precursor, are known to reduce manic
symptoms, although it remains to be established if this is
speciﬁcally due to reducing dopamine levels.97,98 Alpha-methyl-
p-tyrosine, which induces dopamine depletion by inhibition of
tyrosine hydroxylase, also attenuates mania-like symptom in
bipolar patients.99,100
Dopaminergic manipulations and the induction of bipolar
depression
Reserpine and tetrabenazine depletes synaptic dopamine by
irreversibly inhibiting vesicular uptake of monoamines and has
long been known to induce depression.101,102 In addition, a high
prevalence of depression is seen in patients with Parkinson’s
disease and this has been linked to loss of striatal dopaminergic
innervation.103,104 Finally, depletion of tyrosine has been shown to
precipitate depressive symptoms in remitted patients with a
history of major depressive disorder.105,106
MODULATION OF THE DOPAMINE SYSTEM AND TREATMENT
OF BIPOLAR DISORDER
Antidopaminergic drugs in the treatment of mania
Dopamine antagonists and partial agonists are increasingly used
in the treatment of acute mania, bipolar depression and also as
maintenance treatment.107–110 Olanzapine, risperidone, quetia-
pine, aripiprazole, asenapine, ziprasidone and cariprazine have
been approved by the Food and Drug Administration (FDA) as
monotherapy for the treatment of acute mania.111 Pertinently, a
network meta-analysis of 68 randomised controlled trials (RCT),
involving 16 073 participants, addressed the efﬁcacy of different
drugs in the treatment of acute mania. This showed that
dopamine antagonists have larger effect sizes (Haloperidol
(standardised mean difference (SMD) relative to placebo: − 0.56
(95% CI − 0.69 to − 0.43)), risperidone (−0.50 (−0.63 to − 0.38)),
olanzapine (−0.43 (−0.54 to − 0.32)) than mood stabilisers for the
treatment of acute mania (lithium) (−0.37 (−0.63 to − 0.11)),
carbamazepine (–0.36 (–0.60 to − 0.11)), valproate (–0.20 (–0.37
to − 0.04)).14
As the blockade of the dopamine D2/3 receptors is their
common mechanism of action,24 it is likely that reduced
dopamine neurotransmission at least contributes to the clinical
efﬁcacy of these drugs. This assumption is supported by the
greater efﬁcacy of the cis- but not the trans-isomer of clopenthixol
in the treatment of manic symptoms,112 as the cis-isomer is a high
Table 5. Summary of pharmacological evidence on dopamine dysfunction in the bipolar disorder
Phase of illness Drug Mechanism of action Effect
Mania Levodopa Dopamine precursor Induced mania and hypomania in parkinsonian
patients
Bromocriptine Dopamine agonist Induced mania in some patients who received it
for postpartum galactorrhoea
Amphetamine Increases dopamine release Induced mania-like symptom in healthy
volunteers
Dietary tyrosine depletion Reduces dopamine level Reduced manic symptoms in patients
AMPT administration Dopamine depletion Reduced manic symptoms in patients and animal
model
Antidopaminergics D2 blockers Reduces manic symptoms
Euthymia Olanzapine, quetiapine and ziprasidone D2 blockade and 5HT agonism Prolongs remission
Mood stabilisers Act on dopamine downstream
pathways
Prolongs remission
Depression Pramipexole D2/3 agonist Short-term efﬁcacy in bipolar depression
Methylphenidate and amphetamine Increase dopamine release Beneﬁcial in group of bipolar depression patients
with drowsiness and fatigue
Olanzapine-ﬂuoxetine combination,
quetiapine and lurasidone
D2 blockade and serotonergic
effects
Efﬁcacy in bipolar depression
Abbreviation: AMPT, alpha-methyl-p-tyrosine.
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afﬁnity D2/3 receptor blocker while the trans-isomer has much
lower afﬁnity for D2/3 receptors.44,112
Use of antidopaminergic in the maintenance phase
The FDA have approved olanzapine as monotherapy, quetiapine
and ziprasidone as adjunctive therapy, and aripiprazole and
risperidone long acting injections as both adjunctive and
monotherapy for the maintenance treatment of BD.111 Although
lithium and valproate should be preferred, recent guidelines
highlight that dopaminergic drugs have a place in maintenance
treatment.113
Action of non-D2/3 blocker mood stabilisers on dopamine
pathways
Interestingly, it is possible that sodium valproate might exhibit
antimanic effect through an action on the dopaminergic
system.44,45 In a study consisting of 13 manic patients, 2 weeks
of sodium valproate was shown to decrease presynaptic
dopamine synthesis capacity,45 although this was not correlated
with clinical improvement. Interestingly D2/3 density remained
essentially unchanged after valproate treatment,44 despite the
reduction in dopamine synthesis capacity with valproate, which is
anticipated to alter D2/3 availability. Taken together these two
could either suggest valproate blocks the capacity of the D2
receptor to respond to reduced dopamine synthesis, or that the
capacity of D2 receptors to respond is intrinsically impaired in
bipolar disorder. Although both possibilities are speculative at this
stage, the latter is particularly interesting as it suggests that a
failure of D2 adaptation could contribute to the pathophysiology
of bipolar disorder, making the dopamine system more vulnerable
to dopamine transporter driven changes in presynaptic function.
Although the exact mechanism by which lithium acts remains
unclear, it is known to modulate signalling pathways downstream
of dopamine receptors. Preclinical studies have shown that lithium
reverses dopamine dependent behaviour by acting through the
protein kinase B (AKT)/glycogen synthase kinase 3 signalling
cascade.114 Furthermore, lithium acts on the adenyl cyclase and
phospho-inositide, as well as protein kinase C pathways, which are
part of the intracellular signalling pathway downstream of
dopamine receptors.115 In addition, micro-dialysis studies show a
reduction in extracellular dopamine levels in lithium treated
animals.116–118 In summary, there is evidence to suggest that
some non-D2/3 blocking mood stabilisers also act to reduce
dopamine transmission, either through reducing presynaptic
dopamine synthesis capacity in the case of sodium valproate, or
post-synaptic dopaminergic signal transduction in the case of
lithium. The degree to which these effects explain the therapeutic
efﬁcacy of these compounds remains to be determined.
Use of dopaminergic treatments for bipolar depression
Three double-blind placebo-controlled studies have shown that
short-term use of pramipexole, a D2/D3 receptor agonist, is
efﬁcacious as an augmentation strategy for the treatment of
bipolar depression and positive results have also been seen in
other open-label studies.119–127 Although there have not been any
RCTs investigating the efﬁcacy of methylphenidate or ampheta-
mines in bipolar depression, the available open-label and
naturalistic studies point towards a beneﬁt of stimulants in a
selected group of patients with drowsiness and fatigue.128–131
Randomised controlled studies and open-label reports with other
stimulant like agents such as modaﬁnil and its R-enantiomer,
armodaﬁnil also indicate efﬁcacy in bipolar depression although
the development programme for armodaﬁnil failed.132–138 There is
evidence to support the potential use of monoamine oxidase
inhibitors such as tranylcypromine in bipolar depression.139,140 It is
speculated that tranylcypromine acts as dopamine releaser with
about 1/10th the potency of amphetamine.139,140 There are thus
several lines of evidence suggesting that dopaminergic augmen-
tation is beneﬁcial in bipolar depression.
However, there is also evidence that dopamine antagonists are
effective in the treatment of bipolar depression.15 The FDA has
approved the combination of olanzapine and ﬂuoxetine, as well as
monotherapy with quetiapine or lurasidone, for the treatment of
acute bipolar depression. A recent meta-analysis of 24 placebo-
controlled trails (n= 7307) revealed the following order of efﬁcacy
of drugs for the treatment of bipolar depression: olanzapine
+ﬂuoxetine⩾ valproate4quetiapine4lurasidone4olanzapine,
aripiprazole and carbamazepine.141 The analysis is interesting in
showing that antidopaminergics on their own have efﬁcacy in
bipolar depression.
The evidence thus suggests that both dopaminergic agonists
and dopaminergic blockers, are effective in treating bipolar
depression. This presents a paradox for understanding the role
of dopamine in bipolar depression. However, actions at receptors
Figure 1. Summary of dopamine molecular imaging ﬁndings in bipolar disorder.
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other than dopamine ones may underlie the efﬁcacy of the
dopamine blockers. For example, as well as all being D2/3 receptor
blockers, olanzapine and quetiapine are both relatively high
afﬁnity 5HT2A antagonists,
142 whilst both lurasidone and aripipra-
zole have high afﬁnity for 5HT1A receptors.
142,143 Potentially
supporting this explanation, there are no clinical trials reporting
efﬁcacy of pure D2/3 blockers in bipolar depression. Nevertheless,
the doses used in the clinical trials correspond to the dose ranges
associated with substantial dopamine D2/3 receptor occupancy,24
so dopamine receptor blockade is certainly compatible with
antidepressant efﬁcacy. The ﬁnal consideration is that there has
been a relatively small number of good quality RCTs for
antidopaminergic treatment in bipolar depression, certainly in
comparison to studies in mania. Studies that can directly test the
mechanism underlying the mode of action of these drugs and
pramipexole would be of great interest.
DISCUSSION
Our main ﬁndings for bipolar mania are that (i) there is consistent
pharmacological evidence, especially from treatment studies, to
support the hypothesis that a state of hyperdopaminergia can
lead to mania; (ii) imaging studies support this hypothesis, with
several studies reporting elevations in D2/3 receptor availability in
psychotic mania and fMRI imaging evidence that identiﬁes
hyperactivity of the reward circuit in mania. Dopamine synthesis
and receptor density appear to remain unchanged, at least in non-
psychotic mania patients compared with HC.
For bipolar depression (i) pharmacological evidence shows that
dopamine agonists are potentially beneﬁcial for bipolar depres-
sion, but the same seems true for dopamine blocking drugs; (ii)
the imaging studies show replicated increases in dopamine
transporter levels, but there is inconsistency and it is not clear if
there are other alterations as well. Figure 1 summarises our main
imaging ﬁndings for mania and depression.
Finally, post-mortem evidence suggests an upregulation of the
D2/3 receptors in bipolar patients, but interpretation is limited by
lack of information on phase of illness and medication status at
the time of death.
Implications for the dopamine hypothesis of bipolar disorder
More than four decades on from the early conceptualisations of
the dopamine hypothesis of BD, it has stood the test of time,
and the evidence for elements have strengthened. This is
particularly the case for mania where the strength of the clinical
trial evidence for the beneﬁt of dopamine antagonists and partial
agonists, supported by meta-analysis, would require an improb-
ably large number of negative studies for reversal. Added to this
there is now molecular and fMRI imaging evidence in bipolar
disorder. Further, preclinical studies using optogenetic methods
and knockout mice have shown that dopaminergic neuron
activation leads to manic-like behaviour and it is linked to
circadian gene expression.31,144 Tentatively, these studies suggest
elevated D2/3 receptor availability and a hyper-responsive reward
system in ventral striatum in mania, and an increase in striatal
dopamine transporter availability in bipolar depression. Dopamine
neurotransmission in the striatum is primarily terminated by
reuptake of dopamine into the presynaptic dopamine nerve
terminal by dopamine transporters. Thus, an elevation in striatal
D2/3 receptor availability in mania would lead to increased
dopaminergic neurotransmission whilst increased striatal dopa-
mine transporter levels in depression would lead to reduced
dopaminergic function. This suggests a model in which elevated
D2/3 receptor levels lead to altered reward processing and the
development of mania, which is followed by a compensatory
increase in dopamine transporter levels to reduce dopaminergic
neurotransmission. However, if, over time, D2/3 receptor levels
reduce but dopamine transporter levels do not normalise, this
would then lead to reduced dopaminergic transmission, leading
to depression and, in turn, a compensatory upregulation of D2/3
receptor levels, precipitating a further phase switch. One can see
how a failure of homoeostatic regulation of the dopaminergic
system could lead to cyclical periods of elevated and blunted
dopaminergic neurotransmission. This model might apply most
precisely to rapid cycling bipolar disorder. However it could be a
component of all manic episodes, with other systems acting to
disrupt the regular cyclicity that is so obvious in a substantial
number of patients.
We recognise that this model is conjectural at this stage.
Nevertheless, it makes predictions that can be tested empirically.
In particular it predicts longitudinal changes in dopamine
transporter and receptor levels linked to phase switches. Moreover
it predicts that these changes and alterations in reward processing
will pre-date symptom changes. However, many aspects of
dopamine function in bipolar disorder are incompletely char-
acterised. In particular baseline dopamine levels have not been
measured in mania or depression. In addition, psychotic
symptoms may also be present in manic patients, and psychosis
per se may drive dopaminergic changes.40,145 It is worth noting
that, none of the studies have investigated dopamine function in
mixed states. As approximately two thirds of depressed patients
have concomitant manic symptoms,146 any theory needs to
explain mixed states as well as mania and depression. It would be
hard to account for mixed states by dysfunction in dopaminergic
function alone. Interestingly, asenapine seems to be more
effective than olanzapine for mixed episodes.147 As asenapine
has higher afﬁnity for 5HT2A than D2/3 receptors, which could
suggest a role of serotonergic system in mixed episode states.
Finally elevations in D2/3 receptor availability would be predicted
to increase dopaminergic neurotransmission via the indirect
Box 1 Future research direction
1. Animal models exhibiting bipolar depression-like phenotype
need to be developed.
2. Development of better animal models of mood polarity
switching coupled with longitudinal, translational assays
(such as PET, fMRI and behavioural methods).
3. Longitudinal molecular imaging studies investigating dopa-
minergic function, particularly dopamine transporter and
D2/3 receptor homoeostasis, in patients across different
illness phases.
4. Trans-diagnostic comparisons of dopaminergic function in
psychotic and non-psychotic mania and schizophrenia.
5. Imaging studies in mixed states and rapid cycling bipolar
disorder.
6. Longitudinal studies investigating the effects of antidopami-
nergic and conventional mood stabilisers on dopaminergic
pathways and the relationship between dopaminergic
blockade and treatment response in bipolar disorder.
7. Future studies should also focus on integration of data from
molecular imaging studies with functional MRI to elucidate
speciﬁc anatomical circuits involved and the link to molecular
changes.
8. Molecular imaging studies should investigate extra-striatal
dopaminergic changes across different phases of bipolar
disorder.
Abbreviations: fMRI, functional magnetic resonance imaging;
PET, positron emission tomography.
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pathway, and reduce response to cues,148 while the fMRI ﬁndings
in mania do not seem to ﬁt with this. However, the majority of
the patients in these studies were treated with dopamine
antagonists and mood stabilisers (Supplementary Table 2), which
confounds simple interpretation of effects based on dopamine
neurotransmission.
Implications for treatment
If dopamine transmission is increased in mania, the use of D2/3
receptor blockers is logical, but alternative approaches, such as
reducing dopamine synthesis and/or release, are alternative
approaches that may be more effective and/or better tolerated
if they could be sufﬁciently selective. Similarly, selective DAT
blockade could be beneﬁcial for BD depression, at the risk of
precipitating mania. Finally mood stabilisation should improve
homoeostatic regulation of dopaminergic neurotransmission, and
this requires further evaluation and understanding.
Limitations and future directions
The key limitation of the dopamine hypothesis remains that its
strongest supporting evidence comes from pharmacological
studies, which offer an indirect and sometimes imprecise
approach to studying dopaminergic function. Reserpine, alpha-
methyl-para-tyrosine, amphetamine and L-DOPA, for example, can
affect neurotransmission of other monoamines, in particular
norepinephrine, which could contribute to the clinical effects
observed. By the same token, the efﬁcacy of antidopaminergic
drugs in mania may be due to actions at other neurotransmitter
systems, although relatively selective dopamine blockers do
appear to be effective. There is a relative paucity of evidence
from more direct measures, such as molecular imaging studies,
and thus conclusions remain tentative at this stage. Earlier
molecular imaging studies on D2/3 density in mania were
conducted using non-selective ligand [11C]N-methylspiperone,
which has afﬁnity to both D2/3 and 5HT2A receptors.149
Interpretation is further complicated by some studies not being
restricted to one illness phase. Moreover, none of the studies
addressed dopamine transporter availability in mania, dopamine
release in mania or dopamine release in bipolar depression
(summarised in Figure 1).
Although our model suggests euthymia is a state of normalised
dopamine, based on a study demonstrating no signiﬁcant
alteration in the dopamine release paradigm in euthymic patients
compared to controls,50 this is not consistent with the ﬁnding of
elevated DAT in a euthymic state.47 It also remains unclear
whether the dopamine hypothesis can completely explain bipolar
depression and how dopaminergic dysregulation will be linked to
the involvement of other neurotransmitter systems.
A critical limitation is the lack of longitudinal studies that
investigate changes across phases of illness, including mixed
states. Ideally future studies should focus on elucidating phase-
related dopamine dysfunction by studying patients longitudinally
in euthymic, manic and depressive episodes to determine the
direction of causality. Clearly this will be difﬁcult, although a focus
on rapid cycling patients might make it feasible. Cross-sectional
studies are more feasible and could test key elements of the
dopamine hypothesis if well designed. Another key issue is why
some antidopaminergics are effective for bipolar depression.
Molecular imaging studies are needed to determine whether
dopaminergic, serotonergic or other systems are involved in their
mode of action. Finally, although studies have found an effect of
valproate and lithium on dopaminergic function,44,115 it is not
established if this is their mechanism of action. Determining
whether dopaminergic mechanisms are common across classes of
medication would be an important advance in understanding.
Finally, it remains unclear if hyperdopaminergic activity is speciﬁc
to mania or psychosis because many of the manic patients in the
studies had psychotic symptoms as well. It is interesting to note
that in schizophrenia molecular imaging studies indicate there is
an elevation in dopamine synthesis and release capacity, but
unaltered dopamine transporter and D2/3 receptor availability in
striatum.40 PET studies have also demonstrated elevated striatal
dopamine turnover, but blunted cortical and midbrain dopamine
release in schizophrenia.150 In addition, blunting of the fMRI signal
during reward tasks is observed in schizophrenia.85 In contrast,
studies in bipolar disorder suggest dopamine synthesis capacity is
unaltered, at least in non-psychotic mania, but there is elevated
D2/3 receptor availability in psychotic mania. However, direct
comparisons of dopaminergic function in psychotic mania and
schizophrenia as well as longitudinal studies of dopaminergic
activity across various phases of illness are needed to determine if
there are differences between mania and schizophrenia, and
between mania and bipolar depression (Box 1).
CONCLUSIONS
The dopamine hypothesis of bipolar disorder proposes that faulty
homoeostasis between dopamine transporter and receptors
underlies depressive and manic phases of the illness. The available
evidence suggests elevated D2/3 receptor availability and a hyper-
responsive reward system in mania, and possibly increased
dopamine transporter availability in bipolar depression. Future
longitudinal studies are needed to elucidate the precise phase-
related changes in dopaminergic function and the speciﬁcity of
alterations to mania over psychosis.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGMENTS
AHA, TRM and MMN conduct research funded by the Medical Research Council (UK).
TRM received honoraria as a speaker for Lundbeck. SJ conducts research funded by
Medical Research Council (UK) and Wellcome trust. Professor Howes conducts
research funded by the Medical Research Council (UK), the National Institute of
Health Research (UK) and the Maudsley Charity. Professor Goodwin holds a grant
from Wellcome Trust, holds shares in P1vital and has served as consultant, advisor or
CME speaker for AstraZeneca, Merck, Cephalon/Teva, Eli Lilly, Lundbeck, Medscape,
Otsuka, P1Vital, Pﬁzer, Servier, Sunovion, Takeda. He is a NIHR Senior Investigator.
Professor Young has been a consultant to or has received honoraria or grants from
AstraZeneca, Lunbeck, Eli Lilly, Janssen, Servier, Sunovion, Cyberonics and Wyeth.
ODH has received investigator-initiated research funding from and/or participated in
advisory/speaker meetings organised by AstraZeneca, BMS, Eli Lilly, Jansenn,
Lundbeck, Lyden-Delta, Servier, and Roche. The views expressed are those of the
author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
REFERENCES
1 Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA et al.
Psychosocial disability in the course of bipolar I and II disorders: a prospective,
comparative, longitudinal study. Arch Gen Psychiatry 2005; 62: 1322–1330.
2 Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J et al.
Psychosocial disability and work role function compared across the long-term
course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect
Disord 2008; 108: 49–58.
3 Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al. Years lived
with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a
systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;
380: 2163–2196.
4 Merikangas KR, Cui L, Kattan G, Carlson GA, Youngstrom EA, Angst J. Mania with
and without depression in a community sample of US adolescents. Arch Gen
Psychiatry 2012; 69: 943–951.
5 Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA et al. Prevalence and
correlates of bipolar spectrum disorder in the world mental health survey
initiative. Arch Gen Psychiatry 2011; 68: 241–251.
6 Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2015; 387:
1561–1572.
Dopamine hypothesis of bipolar affective disorder
AH Ashok et al
676
Molecular Psychiatry (2017), 666 – 679
7 Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II
disorders in the United States: 2009. J Affect Disord 2011; 129: 79–83.
8 Jann MW. Diagnosis and treatment of bipolar disorders in adults: a review of the
evidence on pharmacologic treatments. Am Health Drug Beneﬁts 2014; 7:
489–499.
9 Alda M. Lithium in the treatment of bipolar disorder: pharmacology and phar-
macogenetics. Mol Psychiatry 2015; 20: 661–670.
10 Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium
therapy for bipolar disorder: systematic review and meta-analysis of randomized
controlled trials. Am J Psychiatry 2004; 161: 217–222.
11 Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006; 11: 227–240.
12 Ketter TA, Miller S, Dell'Osso B, Wang PW. Treatment of bipolar disorder: review
of evidence regarding quetiapine and lithium. J Affect Disord 2016; 191:
256–273.
13 Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M et al. Lithium for
prevention of mood episodes in bipolar disorders: systematic review and
meta-analysis. Int J Bipolar Disord 2014; 2: 15.
14 Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al. Comparative
efﬁcacy and acceptability of antimanic drugs in acute mania: a multiple-
treatments meta-analysis. Lancet 2011; 378: 1306–1315.
15 Young AH, McElroy SL, Olausson B, Paulsson B. A randomised, placebo-
controlled 52-week trial of continued quetiapine treatment in recently depres-
sed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry 2014;
15: 96–112.
16 Giles JJ, Bannigan JG. Teratogenic and developmental effects of lithium. Curr
Pharm Des 2006; 12: 1531–1541.
17 Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety.
Expert Opin Drug Saf 2012; 11: 425–437.
18 McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium
toxicity proﬁle: a systematic review and meta-analysis. Lancet 2012; 379: 721–728.
19 Tissot R. The common pathophysiology of monaminergic psychoses: a new
hypothesis. Neuropsychobiology 1975; 1: 243–260.
20 Wittenborn JR. Deductive approaches to the catecholamine hypothesis of
affective disorders. J Nerv Ment Dis 1974; 158: 320–324.
21 Singh MM. A unifying hypothesis on the biochemical basis of affective disorder.
Psychiatr Q 1970; 44: 706–724.
22 Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F et al.
Dopamine dysregulation syndrome: implications for a dopamine hypothesis of
bipolar disorder. Acta Psychiatr Scand Suppl 2007; (434): 41–49.
23 Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar
Disord 2009; 11: 787–806.
24 Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms
underlying psychosis and antipsychotic treatment response in schizophrenia:
insights from PET and SPECT imaging. Curr Pharm Des 2009; 15: 2550–2559.
25 Harrison PJ, Cipriani A, Harmer CJ, Nobre AC, Saunders K, Goodwin GM et al.
Innovative approaches to bipolar disorder and its treatment. Ann N Y Acad Sci
2016; 1366: 76–89.
26 Berggren U, Tallstedt L, Ahlenius S, Engel J. The effect of lithium on amphetamine-
induced locomotor stimulation. Psychopharmacology 1978; 59: 41–45.
27 Gould TJ, Keith RA, Bhat RV. Differential sensitivity to lithium's reversal of
amphetamine-induced open-ﬁeld activity in two inbred strains of mice. Behav
Brain Res 2001; 118: 95–105.
28 Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ et al. A
reverse-translational study of dysfunctional exploration in psychiatric disorders:
from mice to men. Arch Gen Psychiatry 2009; 66: 1072–1080.
29 Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA. The mania-like
exploratory proﬁle in genetic dopamine transporter mouse models is diminished
in a familiar environment and reinstated by subthreshold psychostimulant
administration. Pharmacol Biochem Behav 2010; 96: 7–15.
30 Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH. Preliminary
evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar
disorder. J Neural Transm 2002; 109: 433–440.
31 Sidor MM, Spencer SM, Dzirasa K, Parekh PK, Tye KM, Warden MR et al. Daytime
spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol Psychiatry
2015; 20: 1406–1419.
32 Winter C, von Rumohr A, Mundt A, Petrus D, Klein J, Lee T et al. Lesions of
dopaminergic neurons in the substantia nigra pars compacta and in the ventral
tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007;
184: 133–141.
33 Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, Finkelstein J et al.
Dopamine neurons modulate neural encoding and expression of depression-
related behaviour. Nature 2013; 493: 537–541.
34 Kaalund SS, Newburn EN, Ye T, Tao R, Li C, Deep-Soboslay A et al. Contrasting
changes in DRD1 and DRD2 splice variant expression in schizophrenia and
affective disorders, and associations with SNPs in postmortem brain.
Mol Psychiatry 2014; 19: 1258–1266.
35 Zhan L, Kerr JR, Lafuente MJ, Maclean A, Chibalina MV, Liu B et al. Altered
expression and coregulation of dopamine signalling genes in schizophrenia and
bipolar disorder. Neuropathol Appl Neurobiol 2011; 37: 206–219.
36 Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, Jarskog LF.
Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizo-
phrenia, bipolar disorder and major depression. Schizophr Res 2010; 118:
292–299.
37 Pantazopoulos H, Stone D, Walsh J, Benes FM. Differences in the cellular
distribution of D1 receptor mRNA in the hippocampus of bipolars and schizo-
phrenics. Synapse 2004; 54: 147–155.
38 Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF. Molecular
abnormalities of the hippocampus in severe psychiatric illness: postmortem
ﬁndings from the Stanley Neuropathology Consortium. Mol Psychiatry 2004; 9:
544.
39 Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is
dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclo-
pride PET study in cats. Neuropsychopharmacology 2009; 34: 662–671.
40 Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. The
nature of dopamine dysfunction in schizophrenia and what this means for
treatment. Arch Gen Psychiatry 2012; 69: 776–786.
41 Pearlson GD, Wong DF, Tune LE, Ross CA, Chase GA, Links JM et al. In vivo D2
dopamine receptor density in psychotic and nonpsychotic patients with bipolar
disorder. Arch Gen Psychiatry 1995; 52: 471–477.
42 Wong DF, Pearlson GD, Tune LE, Young LT, Meltzer CC, Dannals RF et al.
Quantiﬁcation of neuroreceptors in the living human brain: IV. Effect of aging
and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb
Blood Flow Metab 1997; 17: 331–342.
43 Swart JA, van der Werf JF, Wiegman T, Paans AM, Vaalburg W, Korf J. In vivo
binding of spiperone and N-methylspiperone to dopaminergic and serotonergic
sites in the rat brain: multiple modeling and implications for PET scanning.
J Cereb Blood Flow Metab 1990; 10: 297–306.
44 Yatham LN, Liddle PF, Lam RW, Shiah IS, Lane C, Stoessl AJ et al. PET study of the
effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-
stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry 2002; 159:
1718–1723.
45 Yatham LN, Liddle PF, Shiah IS, Lam RW, Ngan E, Scarrow G et al. PET study of
[(18)F]6-ﬂuoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive
ﬁrst-episode nonpsychotic mania: effects of treatment with divalproex sodium.
Am J Psychiatry 2002; 159: 768–774.
46 Anand A, Barkay G, Dzemidzic M, Albrecht D, Karne H, Zheng QH et al. Striatal
dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord
2011; 13: 406–413.
47 Chang TT, Yeh TL, Chiu NT, Chen PS, Huang HY, Yang YK et al. Higher striatal
dopamine transporters in euthymic patients with bipolar disorder: a SPECT study
with [Tc] TRODAT-1. Bipolar Disord 2010; 12: 102–106.
48 Zubieta JK, Huguelet P, Ohl LE, Koeppe RA, Kilbourn MR, Carr JM et al.
High vesicular monoamine transporter binding in asymptomatic bipolar I
disorder: sex differences and cognitive correlates. Am J Psychiatry 2000; 157:
1619–1628.
49 Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A et al. D1 dopamine
receptor binding in mood disorders measured by positron emission tomo-
graphy. Psychopharmacology 1992; 106: 14–18.
50 Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS et al. Brain
SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar
disorder patients. Am J Psychiatry 2000; 157: 1108–1114.
51 Berridge KC. From prediction error to incentive salience: Mesolimbic computa-
tion of reward motivation. Eur J Neurosci 2012; 35: 1124–1143.
52 Schultz W. Dopamine signals for reward value and risk: basic and recent data.
Behav Brain Funct 2010; 6: 1–9.
53 Winton-Brown TT, Fusar-Poli P, Ungless MA, Howes OD. Dopaminergic basis of
salience dysregulation in psychosis. Trends Neurosci 2014; 37: 85–94.
54 Howes OD, Nour MM. Dopamine and the aberrant salience hypothesis of schi-
zophrenia. World Psychiatry 2016; 15: 3–4.
55 Tsai HC, Zhang F, Adamantidis A, Stuber GD, Bonci A, de Lecea L et al. Phasic
ﬁring in dopaminergic neurons is sufﬁcient for behavioral conditioning. Sci-
ence2009; 324: 1080–1084.
56 Schultz W. Updating dopamine reward signals. Curr Opin Neurobiol 2013; 23:
229–238.
57 Schott BH, Minuzzi L, Krebs RM, Elmenhorst D, Lang M, Winz OH et al.
Mesolimbic functional magnetic resonance imaging activations during reward
anticipation correlate with reward-related ventral striatal dopamine release.
J Neurosci 2008; 28: 14311–14319.
Dopamine hypothesis of bipolar affective disorder
AH Ashok et al
677
Molecular Psychiatry (2017), 666 – 679
58 Bartra O, McGuire JT, Kable JW. The valuation system: a coordinate-based meta-
analysis of BOLD fMRI experiments examining neural correlates of subjective
value. NeuroImage 2013; 76: 412–427.
59 Diekhof EK, Kaps L, Falkai P, Gruber O. The role of the human ventral striatum
and the medial orbitofrontal cortex in the representation of reward magnitude -
an activation likelihood estimation meta-analysis of neuroimaging studies of
passive reward expectancy and outcome processing. Neuropsychologia 2012; 50:
1252–1266.
60 Liu X, Hairston J, Schrier M, Fan J. Common and distinct networks underlying
reward valence and processing stages: a meta-analysis of functional neuroi-
maging studies. Neurosci Biobehav Rev 2011; 35: 1219–1236.
61 Nusslock R, Young CB, Damme KSF. Elevated reward-related neural activation as
a unique biological marker of bipolar disorder: assessment and treatment
implications. Behav Res Therapy 2014; 62: 74–87.
62 Aarts E, Roelofs A, Franke B, Rijpkema M, Fernandez G, Helmich RC et al. Striatal
dopamine mediates the interface between motivational and cognitive control in
humans: evidence from genetic imaging. Neuropsychopharmacology 2010; 35:
1943–1951.
63 Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Variation in
dopamine genes inﬂuences responsivity of the human reward system. Proc Natl
Acad Sci USA 2009; 106: 617–622.
64 Forbes EE, Brown SM, Kimak M, Ferrell RE, Manuck SB, Hariri AR. Genetic variation
in components of dopamine neurotransmission impacts ventral striatal reactivity
associated with impulsivity. Mol Psychiatry 2009; 14: 60–70.
65 Jonasson LS, Axelsson J, Riklund K, Braver TS, Ogren M, Backman L et al.
Dopamine release in nucleus accumbens during rewarded task switching
measured by [(1)(1)C]raclopride. NeuroImage 2014; 99: 357–364.
66 Schultz W. Multiple dopamine functions at different time courses. Annu Rev
Neurosci 2007; 30: 259–288.
67 van der Schaaf ME, van Schouwenburg MR, Geurts DE, Schellekens AF, Buitelaar JK,
Verkes RJ et al. Establishing the dopamine dependency of human striatal signals
during reward and punishment reversal learning. Cereb Cortex 2014; 24: 633–642.
68 Knutson B, Gibbs SEB. Linking nucleus accumbens dopamine and blood
oxygenation. Psychopharmacology 2007; 191: 813–822.
69 Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD. Dopamine-dependent
prediction errors underpin reward-seeking behaviour in humans. Nature 2006;
442: 1042–1045.
70 Abler B, Greenhouse I, Ongur D, Walter H, Heckers S. Abnormal reward system
activation in mania. Neuropsychopharmacology 2008; 33: 2217–2227.
71 Bermpohl F, Kahnt T, Dalanay U, Hägele C, Sajonz B, Wegner T et al. Altered
representation of expected value in the orbitofrontal cortex in Mania. Hum Brain
Mapp 2010; 31: 958–969.
72 Caseras X, Lawrence NS, Murphy K, Wise RG, Phillips ML. Ventral striatum activity
in response to reward: differences between bipolar i and II disorders. Am J
Psychiatry 2013; 170: 533–541.
73 Chase HW, Nusslock R, Almeida JR, Forbes EE, Labarbara EJ, Phillips ML. Dis-
sociable patterns of abnormal frontal cortical activation during anticipation of an
uncertain reward or loss in bipolar versus major depression. Bipolar Disord 2013;
15: 839–854.
74 Dutra S, Cunningham W, Kober H, Gruber J. Elevated striatal reactivity across
monetary and social rewards in bipolar I disorder. J Abnorm Psychol 2015; 124:
890–904.
75 Linke J, King AV, Rietschel M, Strohmaier J, Hennerici M, Gass A et al. Increased
medial orbitofrontal and amygdala activation: evidence for a systems-level
endophenotype of bipolar I disorder. Am J Psychiatry 2012; 169: 316–325.
76 Mason L, O'Sullivan N, Montaldi D, Bentall RP, El-Deredy W. Decision-making and
trait impulsivity in bipolar disorder are associated with reduced prefrontal
regulation of striatal reward valuation. Brain 2014; 137: 2346–2355.
77 Nusslock R, Almeida J, Forbes E, Versace A, Frank E, LeBarbara E et al. Waiting
to win: elevated striatal and orbitofrontal cortical activity during reward
anticipation in euthymic bipolar disorder adults. Bipolar Disord 2012; 14:
249–260.
78 Redlich R, Dohm K, Grotegerd D, Opel N, Zwitserlood P, Heindel W et al. Reward
processing in unipolar and bipolar depression: a functional MRI study.
Neuropsychopharmacology 2015; 40: 1–28.
79 Satterthwaite TD, Kable JW, Vandekar L, Katchmar N, Bassett DS, Baldassano CF
et al. Common and dissociable dysfunction of the reward system in bipolar and
unipolar depression reward dysfunction in depression. Neuropsychopharmacol-
ogy 2015; 40: 1–11.
80 Singh MK, Chang KD, Kelley RG, Cui X, Sherdell L, Howe ME et al. Reward
processing in adolescents with bipolar I disorder. J Am Acad Child Adolesc
Psychiatry 2013; 52: 68–83.
81 Trost S, Diekhof EK, Zvonik K, Lewandowski M, Usher J, Keil M et al. Disturbed
anterior prefrontal control of the mesolimbic reward system and increased
impulsivity in bipolar disorder. Neuropsychopharmacology 2014; 39: 1914–1923.
82 Yip SW, Worhunsky PD, Rogers RD, Goodwin GM. Hypoactivation of the ventral
and dorsal striatum during reward and loss anticipation in antipsychotic
and mood stabilizer-naive bipolar disorder. Neuropsychopharmacology 2015; 40:
658–666.
83 Dichter GS, Kozink RV, McClernon FJ, Smoski MJ. Remitted major depression is
characterized by reward network hyperactivation during reward anticipation and
hypoactivation during reward outcomes. J Affect Disord 2012; 136: 1126–1134.
84 Hagele C, Schlagenhauf F, Rapp M, Sterzer P, Beck A, Bermpohl F et al.
Dimensional psychiatry: reward dysfunction and depressive mood across psy-
chiatric disorders. Psychopharmacology 2015; 232: 331–341.
85 Radua J, Schmidt A, Borgwardt S, Heinz A, Schlagenhauf F, McGuire P et al.
Ventral striatal activation during reward processing in psychosis: a neurofunc-
tional meta-analysis. JAMA Psychiatry 2015; 72: 1243–1251.
86 Yan C, Yang T, Yu QJ, Jin Z, Cheung EF, Liu X et al. Rostral medial prefrontal
dysfunctions and consummatory pleasure in schizophrenia: a meta-analysis of
functional imaging studies. Psychiatry Res 2015; 231: 187–196.
87 Asghar SJ, Tanay VA, Baker GB, Greenshaw A, Silverstone PH. Relationship of
plasma amphetamine levels to physiological, subjective, cognitive and bio-
chemical measures in healthy volunteers. Hum Psychopharm 2003; 18: 291–299.
88 Silverstone T. Dopamine in manic depressive illness. A pharmacological synth-
esis. J Affect Disord 1985; 8: 225–231.
89 Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects
as a model for mania. Psychol Med 1986; 16: 323–329.
90 Nurnberger JI Jr., Gershon ES, Simmons S, Ebert M, Kessler LR, Dibble ED et al.
Behavioral, biochemical and neuroendocrine responses to amphetamine in
normal twins and 'well-state' bipolar patients. Psychoneuroendocrinology 1982; 7:
163–176.
91 Ko GN, Leckman JF, Heninger GR. Induction of rapid mood cycling during L-dopa
treatment in a bipolar patient. Am J Psychiatry 1981; 138: 1624–1625.
92 Harsch HH, Miller M, Young LD. Induction of mania by L-dopa in a nonbipolar
patient. J Clin Psychopharmacol 1985; 5: 338–339.
93 Murphy DL. L-dopa, behavioral activation and psychopathology. Res Publ Assoc
Res Nerv Ment Dis 1972; 50: 472–493.
94 Fisher G, Pelonero AL, Ferguson C. Mania precipitated by prednisone and
bromocriptine. Gen Hosp Psychiatry 1991; 13: 345–346.
95 Kemperman CJ, Zwanikken GJ. Psychiatric side effects of bromocriptine therapy
for postpartum galactorrhoea. J R Soc Med 1987; 80: 387–388.
96 Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-
associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull
2008; 41: 37–47.
97 McTavish SF, McPherson MH, Harmer CJ, Clark L, Sharp T, Goodwin GM et al.
Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and
patients with manic illness. Br J Psychiatry 2001; 179: 356–360.
98 Scarna A, Gijsman HJ, McTavish SF, Harmer CJ, Cowen PJ, Goodwin GM. Effects of
a branched-chain amino acid drink in mania. Br J Psychiatry 2003; 182: 210–213.
99 Anand A, Darnell A, Miller HL, Berman RM, Cappiello A, Oren DA et al. Effect of
catecholamine depletion on lithium-induced long-term remission of bipolar
disorder. Biol Psychiatry 1999; 45: 972–978.
100 van Enkhuizen J, Geyer MA, Halberstadt AL, Zhuang X, Young JW. Dopamine
depletion attenuates some behavioral abnormalities in a hyperdopaminergic
mouse model of bipolar disorder. J Affect Disord 2014; 155: 247–254.
101 Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of
supporting evidence. Am J Psychiatry 1965; 122: 509–522.
102 Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication
to treatment with tetrabenazine? Clin Neuropharmacol 2006; 29: 259–264.
103 Martinez-Martin P, Damian J. Parkinson disease: depression and anxiety in
Parkinson disease. Nat Rev Neurol 2010; 6: 243–245.
104 Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's
disease: loss of dopamine and noradrenaline innervation in the limbic system.
Brain 2005; 128: 1314–1322.
105 Parker G, Brotchie H. Mood effects of the amino acids tryptophan and tyrosine:
'Food for Thought' III. Acta Psychiatr Scand 2011; 124: 417–426.
106 Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin,
norepinephrine and dopamine levels in humans: a meta-analysis of monoamine
depletion studies. Mol Psychiatry 2007; 12: 331–359.
107 Greil W, Haberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic
trends in 2231 psychiatric inpatients with bipolar depression from the Interna-
tional AMSP Project between 1994 and 2009. J Affect Disord 2012; 136: 534–542.
108 Hayes J, Prah P, Nazareth I, King M, Walters K, Petersen I et al. Prescribing trends
in bipolar disorder: cohort study in the United Kingdom THIN primary care
database 1995-2009. PloS One 2011; 6: e28725.
109 Hooshmand F, Miller S, Dore J, Wang PW, Hill SJ, Portillo N et al. Trends in
pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.
J Affect Disord 2014; 155: 283–287.
Dopamine hypothesis of bipolar affective disorder
AH Ashok et al
678
Molecular Psychiatry (2017), 666 – 679
110 Walpoth-Niederwanger M, Kemmler G, Grunze H, Weiss U, Hortnagl C, Strauss R
et al. Treatment patterns in inpatients with bipolar disorder at a psychiatric
university hospital over a 9-year period: focus on mood stabilizers. Int Clin
Psychopharmacol 2012; 27: 256–266.
111 Ketter TA, Miller S, Dell'Osso B, Calabrese JR, Frye MA, Citrome L. Balancing
beneﬁts and harms of treatments for acute bipolar depression. J Affect Disord
2014; 169: S24–S33.
112 Nolen WA. Dopamine and mania. The effects of trans- and cis-clopenthixol in a
double-blind pilot study. J Affect Disord 1983; 5: 91–96.
113 Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A et al.
Evidence-based guidelines for treating bipolar disorder: Revised third edition
recommendations from the British Association for Psychopharmacology.
J Psychopharmacol 2016; 30: 495–553.
114 Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR et al.
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen
synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004; 101: 5099–5104.
115 Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of
lithium in bipolar disorder. Current understanding. CNS Drugs 2013; 27: 135–153.
116 Gambarana C, Ghiglieri O, Masi F, Scheggi S, Tagliamonte A, De Montis MG. The
effects of long-term administration of rubidium or lithium on reactivity to stress and
on dopamine output in the nucleus accumbens in rats. Brain Res 1999; 826: 200–209.
117 Ichikawa J, Dai J, Meltzer HY. Lithium differs from anticonvulsant mood stabi-
lizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1 A)
receptor agonism. Brain Res 2005; 1049: 182–190.
118 Ferrie LJ, Gartside SE, Martin KM, Young AH, McQuade R. Effect of chronic lithium
treatment on D2/3 autoreceptor regulation of dopaminergic function in the rat.
Pharmacol Biochem Behav 2008; 90: 218–225.
119 Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK. Placebo-
controlled adjunctive trial of pramipexole in patients with bipolar disorder:
targeting cognitive dysfunction. J Clin Psychiatry 2012; 73: 103–112.
120 Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A et al.
Pramipexole in treatment-resistant depression: an extended follow-up. Depress
Anxiety 2004; 20: 131–138.
121 Dell'osso B, Timtim S, Hooshmand F, Miller S, Wang PW, Hill SJ et al. Superior
chronic tolerability of adjunctive modaﬁnil compared to pramipexole in
treatment-resistant bipolar disorder. J Affect Disord 2013; 150: 130–135.
122 El-Mallakh RS, Penagaluri P, Kantamneni A, Gao Y, Roberts RJ. Long-term use of
pramipexole in bipolar depression: a naturalistic retrospective chart review.
Psychiatr Q 2010; 81: 207–213.
123 Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind,
placebo-controlled trial of pramipexole added to mood stabilizers for treatment-
resistant bipolar depression. Am J Psychiatry 2004; 161: 564–566.
124 Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR et al. Pramipexole in
treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002;
4: 307–314.
125 Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in
treatment-resistant bipolar II depression: an open case series. Pharmaco-
psychiatry 2001; 34: 137–141.
126 Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS et al. Pramipexole
augmentation in the treatment of unipolar and bipolar depression: a retro-
spective chart review. Ann Clin Psychiatry 2000; 12: 137–140.
127 Zarate CA Jr., Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD et al.
Pramipexole for bipolar II depression: a placebo-controlled proof of concept
study. Biol Psychiatry 2004; 56: 54–60.
128 Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with
bipolar disorder: treatment of residual depression and sedation. Bipolar Disord
2004; 6: 416–420.
129 El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar
Disord 2000; 2: 56–59.
130 Lydon E, El-Mallakh RS. Naturalistic long-term use of methylphenidate in bipolar
disorder. J Clin Psychopharmacol 2006; 26: 516–518.
131 Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing
treatment-resistant depression? Acta Psychiatr Scand 2010; 121: 308–314.
132 Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modaﬁnil augmentation
therapy in unipolar and bipolar depression: a systematic review and meta-
analysis of randomized controlled trials. J Clin Psychiatry 2013; 74: 1101–1107.
133 Dell'Osso B, Ketter TA, Cremaschi L, Spagnolin G, Altamura AC. Assessing the
roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment
of bipolar depression. Curr Psychiatry Rep 2013; 15: 378.
134 Rao JS, Kellom M, Reese EA, Rapoport SI, Kim HW. Dysregulated glutamate
and dopamine transporters in postmortem frontal cortex from bipolar and
schizophrenic patients. J Affect Disord 2012; 136: 63–71.
135 Lee FJ, Pei L, Liu F. Disruption of the dopamine transporter-dopamine D2
receptor interaction in schizophrenia. Synapse (New York, NY) 2009; 63: 710–712.
136 Amsterdam JD, Newberg AB. A preliminary study of dopamine transporter
binding in bipolar and unipolar depressed patients and healthy controls. Neuro-
psychobiology 2007; 55: 167–170.
137 Nasr S. Modaﬁnil as adjunctive therapy in depressed outpatients. Ann Clin
Psychiatry 2004; 16: 133–138.
138 Nasr S, Wendt B, Steiner K. Absence of mood switch with and tolerance to
modaﬁnil: a replication study from a large private practice. J Affect Disord 2006;
95: 111–114.
139 Heijnen WT, De Fruyt J, Wierdsma AI, Sienaert P, Birkenhager TK. Efﬁcacy
of tranylcypromine in bipolar depression: a systematic review. J Clin Psycho-
pharmacol 2015; 35: 700–705.
140 Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase
inhibitors in the treatment of depression. CNS Drugs 2013; 27: 789–797.
141 Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar
depression: meta-analyses of placebo-controlled, monotherapy trials of anti-
convulsants, lithium and antipsychotics. Pharmacopsychiatry 2014; 47: 43–52.
142 Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin
Psychiatry 2005; 7: 268–274.
143 Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for
schizophrenia. Expert Opin Investig Drugs 2009; 18: 1715–1726.
144 Chung S, Lee EJ, Yun S, Choe HK, Park SB, Son HJ et al. Impact of circadian
nuclear receptor REV-ERBalpha on midbrain dopamine production and mood
regulation. Cell 2014; 157: 858–868.
145 Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC et al. Abnormal
prefrontal activation directly related to pre-synaptic striatal dopamine dysfunc-
tion in people at clinical high risk for psychosis. Mol Psychiatry 2011; 16: 67–75.
146 Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB et al.
Manic symptoms during depressive episodes in 1,380 patients with bipolar
disorder: ﬁndings from the STEP-BD. Am J Psychiatry 2009; 166: 173–181.
147 Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in
bipolar I patients meeting proxy criteria for moderate-to-severe mixed major
depressive episodes: a post hoc analysis. J Clin Psychiatry 2015; 76: 728–734.
148 Hazy TE, Frank MJ, O'Reilly RC. Neural mechanisms of acquired phasic dopamine
responses in learning. Neurosci Biobehav Rev 2010; 34: 701–720.
149 Hall H, Wedel I, Halldin C, Kopp J, Farde L. Comparison of the in vitro receptor
binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and
human brain membranes. J Neurochem 1990; 55: 2048–2057.
150 Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R
et al. Deﬁcits in prefrontal cortical and extrastriatal dopamine release in
schizophrenia: a positron emission tomographic functional magnetic resonance
imaging study. JAMA Psychiatry 2015; 72: 316–324.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2017
Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)
Dopamine hypothesis of bipolar affective disorder
AH Ashok et al
679
Molecular Psychiatry (2017), 666 – 679
